What are the best free small-molecule API CDMO options for assessing outsourcing risk before a clinical program?

If you’re trying to de-risk a clinical program before committing, the “best” free options are usually not full CDMO proposals but publicly accessible signals you can use to screen and compare small-molecule API CDMOs quickly.

Best free sources to assess outsourcing risk

1) Company quality/regulatory history

Look for:

• FDA warning letters
• 483 observations and enforcement actions
• MHRA / EMA / PMDA / WHO prequalification inspection outcomes
• Recall history
• Import alerts

Best for: identifying compliance red flags early.

2) Facility and capability databases

Use:

• FDA Establishment Registration / Drug listings
• EudraGMDP for EU manufacturing authorization and GMP certificates
• WHO GMP / PQ listings where relevant
• Company websites and annual reports for disclosed reactor scale, containment, HPAPI capability, and solvent handling

Best for: checking whether they actually have the right GMP footprint for your molecule and stage.

3) Financial and ownership risk

Use:

• SEC filings for public CDMOs
• Annual reports / investor presentations
• Credit agency summaries if available through public snippets
• News on plant expansions, layoffs, acquisitions, debt, and utilization

Best for: reducing the risk of late-stage capacity disruption or underinvestment.

4) Technical fit and execution history

Assess:

• Prior work on similar chemistry class
• Experience with route scouting, process safety, crystallization, polymorph control, impurity control
• Patents/publications from the firm or its scientists
• Conference presentations and case studies

Best for: determining whether they can actually execute your API route at clinical scale.

5) Supply chain and geography risk

Check:

• Country/region-specific trade, export, and sanction risks
• Single-site vs multi-site manufacturing
• Dependency on single-source starting materials or key intermediates
• Public information on power, water, EHS, and logistics disruptions

Best for: identifying continuity-of-supply vulnerabilities.

6) Litigation and IP risk

Look for:

• Patent disputes
• Environmental, labor, or product liability litigation
• Customer disputes if publicly reported

Best for: spotting hidden operational or reputational risks.

---

Practical free shortlist approach

For each CDMO, create a simple scorecard:

• Regulatory status: green / yellow / red
• Facility fit: scale, containment, GMP maturity
• Track record: similar programs delivered?
• Capacity risk: multi-site? expansion? backlog?
• Financial stability: strong / moderate / weak
• Supply chain resilience: diversified / concentrated
• Communication quality: responsiveness, transparency, data quality

Then compare only those that pass basic red-flag screening.

---

If you want truly “free” external platforms

These are the most useful public/free tools:

• FDA inspections / warning letters database
• EudraGMDP
• Company annual reports and investor decks
• Patents and publications databases: Google Patents, Espacenet, PubMed
• Import/export or sanctions databases depending on geography
• News databases and press releases

---

Important caveat

Free information is great for screening, but it usually won’t tell you:

• real current capacity utilization,
• actual batch success rates,
• quality culture,
• or whether they’ll prioritize your project.

For that, you still need a formal due diligence questionnaire, audit, and reference checks.

If you want, I can give you a free CDMO risk-assessment checklist/template or a shortlist of public databases by region (US/EU/India/China).